Femasys (FEMY) vs Regentis Biomaterials (RGNT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Femasys is the larger company by market cap ($17.1 million vs $11.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FEMY | RGNT |
|---|---|---|
| Share price | $2.05 | $1.70 |
| Market cap | $17.13M | $11.94M |
| 1-day change | +2.25% | +4.29% |
| YTD return | -82.25% | -74.78% |
| 1-year return | -82.87% | — |
| 5-year return | -98.54% | — |
| EPS (TTM) | $-3.28 | $-2.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.20 | $15.50 |
| 52-week low | $1.94 | $1.23 |
| Distance from 52-week high | -90.79% | -89.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +600.73% | +488.24% |
| Average volume | 721.18K | 76.78K |
| Shares outstanding | 8.38M | 7.02M |
| Employees | 51 | — |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Healthcare · Medical Instruments & Supplies · 51 employees
About Regentis Biomaterials
RGNT stock →Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
Healthcare · Medical Instruments & Supplies
FEMY vs RGNT FAQ
Which is bigger, Femasys or Regentis Biomaterials?
Femasys (FEMY) is larger, with a market capitalization of $17.13M compared with $11.94M for Regentis Biomaterials (RGNT).
Are Femasys and Regentis Biomaterials in the same industry?
Yes. Both are classified in the Medical Instruments & Supplies industry within the Healthcare sector.